Lupus Nephritis: A Major Focus at the Lupus Research Alliance
Updated March, 2022
Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the...
Stories & News
Catch Up on LRA News with Lupus Research Update Vol. 1, 2022
February 17, 2022
It’s with great pride that I share a sampling of the many extraordinary accomplishments of last year...
Lupus Research Alliance Congratulates Dr. Robert Califf on FDA Commissioner Appointment
February 17, 2022
The Lupus Research Alliance applauds the appointment of Dr. Robert Califf as the Commissioner of the U.S....
Encouraging Results with Obinutuzumab for Lupus Nephritis
February 13, 2022
The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive...
LRA-Funded Research Aims at Preventing Heart Disease in Kids With Lupus
February 14, 2022
Being a kid isn't always easy, but growing up with lupus makes it a much harder challenge....
LRA-Funded Research Found a Connection Between the Epstein-Barr Virus Infection and MS as an Autoimmune Disease
February 4, 2022
A potential new cause of the autoimmune disease multiple sclerosis (MS) was discovered by researchers partly funded...
Baricitinib Development as a Lupus Treatment Discontinued
January 28, 2022
The Lupus Research Alliance is disappointed that the Phase 3 development program of OLUMIANT® (baricitinib) as a...
LRA-Funded Research Uncovers a Novel Pathway for Lupus Nephritis
January 28, 2022
The investigators from The Accelerated Medicines Partnership® Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Program, in...
Shingles Vaccine Recommended for Immunocompromised People
January, 2022
As of January, 2022, the U.S. Centers for Disease Control and Prevention (CDC) recommends the use of the...
FDA Authorizes Evusheld Emergency Use to Prevent COVID-19 in Immunocompromised Patients
December 9, 2021
People with lupus can be immunocompromised because of the disease itself or medications that suppress the immune...
Aurinia Announces Positive Long-Term Results on Lupykinis™ for Lupus Nephritis
December 9, 2021
The LRA is pleased to share positive topline three-year efficacy and safety results reported today by Aurinia...
LRA Partnering with NIH, FNIH and Others on Groundbreaking Initiative
December 9, 2021
The Lupus Research Alliance (LRA) is proud and excited to partner again with the National Institutes of...